The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September

The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September

Shares of NewLink Genetics (NASDAQ: NLNK), a small-cap clinical-stage drug developer focused on therapies to treat cancer, skyrocketed by 25% in September, according to data from S&P Global Market Intelligence. The clear reason for the move higher is tied to an early month press release that updated trial data from an ongoing phase 2 study involving its lead drug indoximod.

The updated data, which NewLink presented at the Third International Cancer Immunotherapy Conference in Frankfurt/Mainz, Germany on Sept. 9, yielded encouraging and improved results for the company's IDO inhibitor in combination with Merck's (NYSE: MRK) cancer immunotherapy Keytruda.

Image source: Getty Images.

Continue reading

Source: Fool.com